FDA Plans Further Audits Of Telavancin Study Sites; No Major Problems To Date
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm says FDA and company audits of telavancin clinical trial data are progressing well; no predictions on how long process may take.
You may also be interested in...
Burned By Ketek, FDA Took Care With Possible Data Integrity Issues For Telavancin
Congressional investigations into FDA's handling of data integrity issues with a safety trial for Sanofi-Aventis' antibiotic Ketek caught Theravance's pending antibiotic Vibativ (telavancin) in its wake, FDA review documents reveal
Burned By Ketek, FDA Took Care With Possible Data Integrity Issues For Telavancin
Congressional investigations into FDA's handling of data integrity issues with a safety trial for Sanofi-Aventis' antibiotic Ketek caught Theravance's pending antibiotic Vibativ (telavancin) in its wake, FDA review documents reveal
Theravance’s Telavancin Data Integrity Issues Resolved; FDA Review Back On Track
FDA will resume the review of Theravance’s antibiotic telavancin at a three-day advisory committee meeting in November after completing an audit of the company’s clinical trial data.